Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 6/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.33 |
| ▸ | TACR2 | P21452 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.33 |
| ▸ | SHBG | P04278 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.33 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10168052 | 0.89 | LMNA (0.37) | LMNATAAR1 | |
| SCHEMBL27195609 | 0.84 | ESR1 (0.42) | LMNAESR1ALDH1A1KDM4EADRA2A | |
| SCHEMBL28755747 | 0.81 | PTGS2 (0.34) | LMNAESR1ADRB3PTGS1PTGS2 | |
| SCHEMBL28755748 | 0.80 | LMNA (0.32) | LMNA | |
| SCHEMBL8060462 | 0.76 | LMNA (0.47) | LMNAALDH1A1CYP3A4CYP2C19KMT2A | |
| SCHEMBL22179402 | 0.66 | CNR2 (0.32) | — | |
| SCHEMBL26554557 | 0.63 | CA2 (0.37) | LMNACA2ESR1ESR2ALDH1A1 | |
| SCHEMBL13558751 | 0.63 | PRKCA (0.36) | LMNAALDH1A1HSD17B10 | |
| SCHEMBL29053739 | 0.60 | ESR1 (0.43) | LMNACA2ESR1ESR2ALDH1A1 | |
| SCHEMBL13923732 | 0.59 | ESR1 (0.60) | LMNACA2ESR1ESR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2509938-A1 | FTY720 HALOGENATED DERIVATIVES | Novartis AG (CH) | 2012-10-17 | — | — | EP | disclosed |
| US-20120244071-A1 | FTY720 HALOGENATED DERIVATIVES | NOVARTIS AG (CH) | 2012-09-27 | — | — | US | disclosed |
| US-20120244071-A1 | FTY720 HALOGENATED DERIVATIVES | NOVARTIS AG (CH) | 2012-09-27 | — | — | US | disclosed |
| US-20120244071-A1 | FTY720 HALOGENATED DERIVATIVES | NOVARTIS AG (CH) | 2012-09-27 | — | — | US | disclosed |
| EP-1622860-B1 | AMINO-PROPANOL DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE RECEPTOR MODULATORs | NOVARTIS AG (CH) | 2012-02-29 | — | — | EP | disclosed |
| WO-2011070066-A1 | FTY720 HALOGENATED DERIVATIVES | NOVARTIS AG (CH) | 2011-06-16 | — | — | WO | disclosed |
| WO-2011070066-A1 | FTY720 HALOGENATED DERIVATIVES | NOVARTIS AG (CH) | 2011-06-16 | — | — | WO | disclosed |
| US-7625950-B2 | Mono phosphoric acid mono-{2-amino-2-hydroxymethyl-4-[4-(3-phenoxy-propoxy)-phenyl]-butyl} ester; treatment, prevention of diseases or disorders mediated by lymphocytes interactions in transplantation; anticarcinogenic agent, antiinflammatory agent, antiproliferative agent, antidiabetic agent | NOVARTIS AG (CH) | 2009-12-01 | — | — | US | disclosed |
| US-7612238-B2 | Such as (R)-2-amino-2-methyl-4-[4-(4,4,5,5,5-pentafluoro-pentyloxy)-phenyl]-butan-1-ol hydrochloride for treatment of disorders or diseases mediated by lymphocytes, and for treating acute or chronic transplant rejection or T-cell-mediated inflammatory or autoimmune diseases | NOVARTIS AG (CH) | 2009-11-03 | — | — | US | disclosed |
| US-7612238-B2 | Such as (R)-2-amino-2-methyl-4-[4-(4,4,5,5,5-pentafluoro-pentyloxy)-phenyl]-butan-1-ol hydrochloride for treatment of disorders or diseases mediated by lymphocytes, and for treating acute or chronic transplant rejection or T-cell-mediated inflammatory or autoimmune diseases | NOVARTIS AG (CH) | 2009-11-03 | — | — | US | disclosed |
| CN-100516024-C | Amino-propanol derivatives | NOVARTIS AG (CH) | 2009-07-22 | — | — | CN | disclosed |
| US-20060211658-A1 | Amino-propanol derivatives as sphingosine-1-phosphate receptor modulator | NOVARTIS AG (CH) | 2006-09-21 | — | — | US | disclosed |
| US-20060166940-A1 | Amino-propanol derivatives | NOVARTIS AG (CH) | 2006-07-27 | — | — | US | disclosed |
| EP-1660449-A1 | AMINOPROPANOL DERIVATIVES | Novartis AG (CH) | 2006-05-31 | — | — | EP | disclosed |
| EP-1622860-A1 | AMINO-PROPANOL DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE RECEPTOR MODULATOR | Novartis AG (CH) | 2006-02-08 | — | — | EP | disclosed |
| CN-1681770-A | Amino-propanol derivatives | NOVARTIS AG (CH) | 2005-10-12 | — | — | CN | disclosed |
| EP-1539674-A1 | AMINO-PROPANOL DERIVATIVES | Novartis AG (CH) | 2005-06-15 | — | — | EP | disclosed |
| WO-2005021503-A1 | AMINOPROPANOL DERIVATIVES | NOVARTIS AG (CH) | 2005-03-10 | — | — | WO | disclosed |
| WO-2004096752-A1 | AMINO-PROPANOL DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE RECEPTOR MODULATOR | NOVARTIS AG (CH) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004024673-A1 | AMINO-PROPANOL DERIVATIVES | NOVARTIS AG (CH) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166940-A1 | Amino-propanol derivatives | ADRB1, ADRB3, ADRA1D | LMNA 3370/4885CA2 4466/4885ESR1 948/4885 |
| US-20060211658-A1 | Amino-propanol derivatives as sphingosine-1-phosphate receptor modulator | S1PR1, S1PR3, S1PR2 | LMNA 2440/4885CA2 4146/4885ESR1 925/4885 |
| US-20120244071-A1 | FTY720 HALOGENATED DERIVATIVES | S1PR1, S1PR3, S1PR2 | LMNA 4349/4885CA2 4691/4885ESR1 2855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.